Literature DB >> 1504747

Effects of glucose, insulin or aldose reductase inhibition on responses to endothelin-1 of aortic rings from streptozotocin-induced diabetic rats.

W C Hodgson1, R G King.   

Abstract

1. This study investigated the constrictor responsiveness to endothelin-1 (ET-1, 0.1 nM-0.1 microM) of aortic rings (under 10 g resting tension in Krebs solution) from 2- and 6-week streptozotocin (STZ, 60 mg kg-1, i.v.)-induced diabetic rats and vehicle-treated control rats. 2. In aortae from 2- and 6-week STZ-treated rats, and their corresponding controls, removal of endothelium caused leftward shifts of ET-1 concentration-response curves without affecting maximum responses. 3. Maximum responses to ET-1 were reduced in aortae from both 2- and 6-week STZ-treated rats compared to those from control rats. Such reductions were still evident after removal of the endothelium. 4. Decreased responsiveness to ET-1 of aortae from 2-week STZ-treated rats was still evident after chronic treatment with the aldose reductase inhibitor epalrestat, but not after chronic insulin treatment or in aortae bathed in high glucose (30 mM) Krebs solution. 5. Decreased responsiveness to ET-1 of aortae from 6-week STZ-treated rats (compared with those from controls) was still evident after chronic epalrestat treatment and in high glucose Krebs solution. 6. These data suggest that the decreased responsiveness to ET-1 observed in aortae from 2- and 6-week STZ-induced diabetic rats is not due to abnormal activity of the polyol pathway. The altered responsiveness in aortae from 2-week diabetic rats (compared with those from control rats) may possibly be a manifestation of changes (adaptive or otherwise) which occur as a result of high glucose concentrations in vivo.However, in aortae from rats with diabetes of longer duration, other mechanisms may also play a role in the altered responsiveness, since it was no longer reversible by bathing in high glucose Krebs solution.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1504747      PMCID: PMC1907582          DOI: 10.1111/j.1476-5381.1992.tb14389.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  16 in total

1.  Enhanced secretion of endothelin-1 by elevated glucose levels from cultured bovine aortic endothelial cells.

Authors:  T Yamauchi; K Ohnaka; R Takayanagi; F Umeda; H Nawata
Journal:  FEBS Lett       Date:  1990-07-02       Impact factor: 4.124

2.  Glucose-induced microvascular functional changes in nondiabetic rats are stereospecific and are prevented by an aldose reductase inhibitor.

Authors:  J R Williamson; E Ostrow; D Eades; K Chang; W Allison; C Kilo; W R Sherman
Journal:  J Clin Invest       Date:  1990-04       Impact factor: 14.808

3.  Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats.

Authors:  M J Mulvany; W Halpern
Journal:  Circ Res       Date:  1977-07       Impact factor: 17.367

4.  Introduction: evidence for the role of the polyol pathway in the pathophysiology of diabetic complications.

Authors:  T A Beyer; N J Hutson
Journal:  Metabolism       Date:  1986-04       Impact factor: 8.694

5.  Activation of human erythrocyte, brain, aorta, muscle, and ocular tissue aldose reductase.

Authors:  S K Srivastava; N H Ansari; G A Hair; S Awasthi; B Das
Journal:  Metabolism       Date:  1986-04       Impact factor: 8.694

Review 6.  Drugs producing diabetes through damage of the insulin secreting cells.

Authors:  C C Rerup
Journal:  Pharmacol Rev       Date:  1970-12       Impact factor: 25.468

7.  Prevention of peripheral nerve dysfunction by an aldose reductase inhibitor in streptozotocin-diabetic rats.

Authors:  R Kikkawa; I Hatanaka; H Yasuda; N Kobayashi; Y Shigeta
Journal:  Metabolism       Date:  1984-03       Impact factor: 8.694

8.  Modulation by endothelium of the responses induced by endothelin-1 and by some of its analogues in rat isolated aorta.

Authors:  S Topouzis; J P Huggins; J T Pelton; R C Miller
Journal:  Br J Pharmacol       Date:  1991-02       Impact factor: 8.739

9.  Effect of glucose and insulin on immunoreactive endothelin-1 release from cultured porcine aortic endothelial cells.

Authors:  Y Hattori; K Kasai; T Nakamura; T Emoto; S Shimoda
Journal:  Metabolism       Date:  1991-02       Impact factor: 8.694

10.  Attenuated responses to endothelin-1, KCl and CaCl2, but not noradrenaline, of aortae from rats with streptozotocin-induced diabetes mellitus.

Authors:  D J Fulton; W C Hodgson; B W Sikorski; R G King
Journal:  Br J Pharmacol       Date:  1991-12       Impact factor: 8.739

View more
  5 in total

1.  The potential contribution of endothelin-1 to neurovascular abnormalities in streptozotocin-diabetic rats.

Authors:  N E Cameron; K C Dines; M A Cotter
Journal:  Diabetologia       Date:  1994-12       Impact factor: 10.122

2.  Effect of diabetes and elevated glucose on nitric oxide-mediated neurotransmission in rat anococcygeus muscle.

Authors:  K J Way; J J Reid
Journal:  Br J Pharmacol       Date:  1995-06       Impact factor: 8.739

3.  Attenuated 5-hydroxytryptamine receptor-mediated responses in aortae from streptozotocin-induced diabetic rats.

Authors:  G M James; W C Hodgson; E A Davis; J M Haynes
Journal:  Br J Pharmacol       Date:  1994-01       Impact factor: 8.739

4.  Prevention by insulin treatment of endothelial dysfunction but not enhanced noradrenaline-induced contractility in mesenteric resistance arteries from streptozotocin-induced diabetic rats.

Authors:  P D Taylor; B B Oon; C R Thomas; L Poston
Journal:  Br J Pharmacol       Date:  1994-01       Impact factor: 8.739

5.  Potentiation by endothelin-1 of 5-hydroxytryptamine responses in aortae from streptozotocin-diabetic rats: a role for thromboxane A2.

Authors:  G M James; W C Hodgson
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.